课题基金 / 基金详情

Research Training in Infections and Immunity

Research Training in Infections and Immunity
感染和免疫研究培训
批准号:
6785203
负责人:
David John Tweardy
金额:
$12.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-01 至 2008-07-31

项目摘要

项目成果

David John Tweardy的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):这是一项新的nssa申请,每年支持两名博士后学员,为期五年。该奖项将大大增加有才华的学员在贝勒医学院从事传染病研究培训的优秀机会。目前,在贝勒医学院或德克萨斯医学中心内,没有NRSA存在于非艾滋病感染的临床研究培训中。然而,对训练有素的专业人员的需求日益增加,他们能够进行临床研究,以治疗和预防威胁美国公民健康的非艾滋病感染,包括感染性肠胃炎和肺炎等古老的祸害以及生物恐怖主义构成的新威胁。贝勒医学院在包括生物防御在内的许多领域都有极好的培训机会。具有良好联邦资助记录和培训经验的参与项目包括:1)先天免疫和医院感染;2)寄生虫感染;3)病毒性和细菌性肠胃炎;4)病毒致癌;5)急性呼吸道病原体;6)疫苗评价;7)肺结核;8)幽门螺杆菌感染;9)假体感染。2002年参与NRSA计划的特定中心和计划的总奖助金支持额为19,769,825美元。感染和免疫研究培训计划的结构将包含三个组成部分,代表受训者可以追求的一般培训轨道:1)基于实验室的临床研究;2)临床研究试验;3)临床流行病学。所有学员将被鼓励参加贝勒医学院的临床科学家培训计划,并获得临床研究硕士学位。那些追求临床流行病学的人可以选择在德克萨斯大学休斯顿分校公共卫生学院攻读公共卫生硕士学位。贝勒医学院(Baylor College of Medicine)的成人传染病培训项目(Adult Infectious Diseases Training Program)表明,它可以吸引高素质的博士后学员,其中一半是女性,近四分之一是未被充分代表的少数族裔,并为他们指明未来传染病临床研究的方向。在过去两年中,该项目培养的毕业生成功地完成了所提出的三个培训途径。这四个人总共发表了26篇经过同行评审的原创手稿,并获得了几项著名的赠款和职业发展奖,共计1,862,500美元。这一最近的记录是作为支持每年两名博士后培训生请求的证据。
英文摘要
DESCRIPTION (provided by applicant): This is a new NRSA application to support two postdoctoral trainees per year for five years This award will substantially increase the ability of talented trainees to exploit outstanding opportunities to pursue research training in infectious diseases at Baylor College of Medicine. At this time, no NRSA exists within Baylor College of Medicine or the Texas Medical Center to pursue clinical research training in non-AIDS infections. Yet, there is increasing need for trained professionals capable of performing clinically based research directed at treatment and prevention of non-AIDS infections that threaten the health of US citizens, including age-old scourges such as infectious gastroenteritis and pneumonia and new threats posed by bioterrorism. Superb training opportunities exist at Baylor College of Medicine in a number of areas, including biodefense. Participating projects with a strong record of federal funding and training experience include: 1) Innate Immunity and Nosocomial Infections; 2) Parasitic Infections; 3) Viral and Bacterial Gastroenteritis; 4) Viral Oncogenesis; 5) Acute Respiratory Pathogens; 6) Vaccine Evaluations; 7) Tuberculosis; 8) Helicobacter pylori Infection; and 9) Prostheses Infections. Total grant support in 2002 for the specific centers and programs participating in this NRSA Program is $19,769,825. The structure of the Program for Research Training in Infections and Immunity will contain three components that represent general training tracks that can be pursued by trainees: 1) laboratory-based clinical research; 2) clinical research trials; and 3) clinical epidemiology. All trainees will be encouraged to participate in the Clinical Scientist Training Program at Baylor College of Medicine and obtain their Masters Degree in Clinical Investigation. Those pursuing the clinical epidemiology track may opt for a MPH Degree at the University of Texas-Houston School of Public Health. The Adult Infectious Diseases Training Program at Baylor College of Medicine has shown it can attract highly qualified postdoctoral trainees, half of them women and close to a quarter underrepresented minorities, and point them in the direction of future infectious diseases clinical research. In the past two years, this program has produced graduates who have successfully pursued each of the three training pathways proposed. Altogether, these four individuals have published 26 original peer-reviewed manuscripts and have been awarded several prestigious grants and career development awards, totaling $1,862,500. This recent track record is offered as evidence in support of the request for two postdoctoral trainees per year.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 2: Targeting STAT3 to Prevent Colorectal Cancer (CRC) in Hereditary Syndromes and Inflammatory Bowel Disease
Project 2: Targeting STAT3 with an Oral Small Molecule to Treat HCC
Project 2: Targeting STAT3 with an Oral Small Molecule to Treat HCC
Project 2: Targeting STAT3 with an Oral Small Molecule to Treat HCC
海外基金